Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as FID 123320 Ophthalmic Solution, Apraclonidine Hydrochloride Ophthalmic Solution
FID 123320 · 1 trial · 2 indications
Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale. This is a co-primary endpoint.
Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale. This is a co-primary endpoint.
Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale.
| Arm | Type | Description |
|---|---|---|
| FID 123320 Ophthalmic Solution - Adult Cohort | EXPERIMENTAL | 1 drop instilled in each eye at Visit 2 (Day 1), followed by one drop instilled in each eye twice a day (approximately 12 hours apart) Day 2 up to Visit 5 (Day 56), followed by 1 drop instilled in each eye at Visit 5 (Day 56). |
| Vehicle - Adult Cohort | PLACEBO_COMPARATOR | 1 drop instilled in each eye at Visit 2 (Day 1), followed by one drop instilled in each eye twice a day (approximately 12 hours apart) Day 2 up to Visit 5 (Day 56), followed by 1 drop instilled in each eye at Visit 5 (Day 56). |
| FID 123320 Ophthalmic Solution - Pediatric Cohort | EXPERIMENTAL | 1 drop instilled in each eye at Visit 2 (Day 1), followed by one drop instilled in each eye twice a day (approximately 12 hours apart) Day 2 up to Visit 5 (Day 56), followed by 1 drop instilled in each eye at Visit 5 (Day 56). |
| Vehicle - Pediatric Cohort | PLACEBO_COMPARATOR | 1 drop instilled in each eye at Visit 2 (Day 1), followed by one drop instilled in each eye twice a day (approximately 12 hours apart) Day 2 up to Visit 5 (Day 56), followed by 1 drop instilled in each eye at Visit 5 (Day 56). |
| Name | Type | Description |
|---|---|---|
| FID 123320 Ophthalmic Solution | DRUG | Investigational sterile aqueous solution |
| Vehicle | DRUG | FID 123320 Ophthalmic Solution inactive ingredients |
Key Inclusion Criteria - Adult Cohort: * Capable of giving signed informed consent; * Willing and able to follow all instructions and attend all study visits; * Able to self-administer eye drops in the opinion of the investigator; * Have a history of vasoconstrictor (redness relief drop) use within...
FID 123320 is an investigational small molecule developed by Alcon Inc. (ticker ALC) as an ophthalmic solution for reducing ocular redness. It is being studied in a Phase 3 clinical program and is not yet approved. The completed trial enrolled 283 participants, including pediatric and adult populations.
FID 123320 is being developed to reduce ocular redness, also described as eye irritation. Alcon Inc. is studying the ophthalmic solution in both pediatric and adult populations. The Phase 3 trial listed ocular redness and eye irritation as the conditions under investigation.
FID 123320 is developed by Alcon Inc., which trades under the ticker ALC. Alcon is an ophthalmology-focused company, and FID 123320 is its investigational ophthalmic solution for ocular redness. The program has completed one Phase 3 trial in the United States.
FID 123320 is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The study was randomized, double-blind, and placebo-controlled, enrolling 283 participants. FID 123320 remains investigational and has not been approved for marketing.
FID 123320 has been studied in the Phase 3 trial NCT06538662, titled an investigation of FID 123320 for the reduction of ocular redness in pediatric and adult populations. The trial is completed, enrolled 283 participants, and was conducted in the United States. It included participants aged 5 years and older.
Yes, FID 123320 Ophthalmic Solution is another name for FID 123320. Both refer to the same investigational small molecule from Alcon Inc. that is being developed in a topical ophthalmic formulation for reducing ocular redness.